RECURSION PHARMACEUTICALS, INC. (RXRX)

Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives, operating with a limited operating history and no products yet approved for commercial sale. The company has advanced a portfolio of differentiated internal drug discovery programs alongside strategic partnerships, all powered by its integrated drug discovery and development platform, the Recursion Operating System (OS). This platform delivers end-to-end, AI-native capabilities spanning from novel biological ideas through clinical development, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development, with the goal of translating complex science into medicines faster, better, and at scale.

A key strategic partnership is a transformational collaboration launched in 2021 with Roche and Genentech, which created the world's first neuromap, a comprehensive machine-learning-powered neuronal data model aimed at uncovering insights into neurodegenerative diseases. Building on this, in 2025 the collaboration achieved a further milestone with the launch of the world's first microglia map, exploring the whole genome within microglia (the brain's resident immune cells) to better understand neuroinflammation and neurodegenerative disease mechanisms, offering new avenues for target and pathway discovery. The company has also engaged in a business combination with Exscientia, which included a global access commitments agreement with the Bill & Melinda Gates Foundation, under which Recursion could be required to repurchase or facilitate the purchase of Class A common stock issued to the Foundation if it defaults on related commitments.

Financially, Recursion has incurred significant operating losses, has not generated product sales revenue, and anticipates continued losses, necessitating substantial additional capital that could result in stockholder dilution, operational restrictions, or relinquishment of rights to its technologies or drug candidates. The company faces numerous risks common to clinical-stage biotechnology and TechBio firms, including uncertainties in drug discovery and clinical development (such as its inferential, AI-driven approach to identifying mechanisms of action), reliance on third parties for manufacturing and clinical trial conduct, dependence on collaborations for development and commercialization, and challenges in obtaining and maintaining robust intellectual property protection. Additional risk areas include platform and data-related vulnerabilities such as cybersecurity threats, reliance on open source software, and risks tied to the use of artificial intelligence and machine learning; commercialization risks including market acceptance and building sales capabilities; regulatory risks spanning FDA and international approval processes, data privacy laws, and AI-related regulatory developments; and risks associated with its acquisitions, including whether anticipated benefits from the Exscientia combination will be realized and challenges of international operations.

The company has also identified material weaknesses in its internal control over financial reporting and faces risks related to attracting and retaining key personnel. Key technological assets referenced include the BioHive-2 supercomputer, Recursion OS, and a digital chemistry platform, all central to the company's strategy of scaling like a technology company while expanding its drug candidate pipeline.